MDA and ACR20 Best Discriminate Treatment Response in PsA
Specific measures help identify effective treatments for psoriatic arthritis
Meta-analysis of 24 trials finds MDA and ACR20 outperform DAPSA and CPDAI in distinguishing active PsA treatments from placebo.
New data identifies which specific measurement tools best distinguish active treatments from placebos for people with psoriatic arthritis.
Integrated biomarker panels provide more complete insights into mechanism-specific therapeutic responses in rheumatoid arthritis
New markers could help predict how rheumatoid arthritis drugs work
This narrative review evaluates conventional and emerging biomarkers for predicting treatment response and resistance in patients with rheum…
Doctors are looking at new biological markers to better predict which treatments will actually work for people with rheumatoid arthritis.
JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis
Specific Biologic Drugs Show Better Results for Rheumatoid Arthritis
This meta-analysis of 99 studies evaluated patient-reported outcomes (PROs) in patients with rheumatoid arthritis treated with b/tsDMARDs. T…
New analysis shows that certain types of biologic drugs may better reduce activity limits and improve mental health for people with rheumato…